Soluble Transferrin Receptor (sTfR) Test

Your ferritin looks fine, your doctor says your iron is normal, and yet you are exhausted. If you have any chronic inflammatory condition, from arthritis to Crohn's disease to heart failure, there is a good chance your standard iron labs are lying to you. Ferritin, the most commonly ordered iron marker, doubles as an inflammation alarm. When inflammation is present, ferritin rises regardless of how much iron your body actually has, masking a deficiency that may be draining your energy and starving your bone marrow.

Soluble transferrin receptor (sTfR) exposes what ferritin hides. It measures a fragment of the receptor that developing red blood cells use to grab iron from the bloodstream. When your cells are hungry for iron, they produce more of these receptors, and fragments break off into your blood. A high sTfR level tells you that your bone marrow is scrambling for iron, even if your ferritin number suggests everything is fine.

What sTfR Actually Measures

About 80% of the sTfR circulating in your blood comes from red blood cell precursors in your bone marrow, specifically from immature red blood cells called erythroblasts. When these cells need more iron to build hemoglobin (the oxygen-carrying protein inside red blood cells), they ramp up production of transferrin receptors on their surface. These receptors act like hands reaching out to grab iron-loaded transferrin, the body's main iron transport protein. As receptor production increases, more fragments are clipped off and released into the bloodstream.

This means sTfR reflects two things simultaneously: how actively your bone marrow is producing red blood cells, and how desperate those cells are for iron. A rising sTfR level is your bone marrow sending up a flare that it cannot get enough iron to do its job.

Why Standard Iron Tests Miss the Problem

Ferritin is the go-to marker for iron status, and for most healthy people it works well. Low ferritin means low iron stores. But ferritin is also what scientists call an acute phase reactant: your body pumps out more of it whenever inflammation is present, regardless of your actual iron stores. If you have rheumatoid arthritis, inflammatory bowel disease, chronic kidney disease, an active infection, or even obesity, your ferritin can be elevated while your tissues are genuinely iron-starved.

This is the diagnostic gap sTfR fills. Because sTfR production is driven primarily by cellular iron demand rather than inflammation, it stays elevated when tissues need iron, even while ferritin is being pushed up by inflammation. A meta-analysis of 18 studies found that sTfR has 86% sensitivity and 75% specificity for identifying iron deficiency anemia, and the diagnostic odds ratio (a measure of how well the test separates iron deficiency from other types of anemia) for distinguishing iron deficiency from anemia caused by chronic disease was 22.9.

The sTfR/Ferritin Index: Greater Than Either Test Alone

The most powerful use of sTfR is not as a standalone number but combined with ferritin in a calculated ratio called the sTfR/log ferritin index (also called the sTfR-F index). You divide your sTfR value by the logarithm of your ferritin level. This ratio exploits the fact that ferritin and sTfR move in opposite directions during iron deficiency: ferritin drops while sTfR rises. When ferritin, sTfR, and the index are used together, the sensitivity for detecting iron deficiency jumps from 41% with ferritin alone to 92% with all three parameters combined.

An sTfR-F index above 2 strongly suggests iron deficiency, even in someone with inflammatory disease. An index below 1 points toward anemia of chronic disease without true iron depletion. This distinction matters because the treatment is entirely different: iron deficiency requires iron replacement, while anemia of chronic disease requires treating the underlying inflammation.

Heart Disease Risk

Elevated sTfR is not just a marker of iron deficiency. It independently predicts cardiovascular events and death, even after accounting for standard risk factors. In the AtheroGene study of 3,423 patients with documented coronary artery disease followed for a median of 4 years, each unit increase in sTfR was associated with a 27% higher risk of cardiovascular death or heart attack (HR 1.27, 95% CI 1.11 to 1.44). This association held after adjusting for body mass index, smoking, hypertension, diabetes, dyslipidemia, C-reactive protein, hemoglobin, and markers of cardiac function.

A longer-term study following 1,480 patients with stable coronary artery disease for nearly 10 years found a J-shaped relationship: both the lowest and highest sTfR levels predicted higher mortality. Those in the highest quarter of sTfR values had a 76% higher risk of death compared to those in the middle range (HR 1.76, 95% CI 1.39 to 2.22). This J-shaped pattern suggests that both iron deficiency (high sTfR) and suppressed bone marrow activity (very low sTfR) carry risk.

Heart Failure

The prognostic power of sTfR is particularly striking in heart failure. In a study of 791 patients with heart failure and reduced pumping function, those with sTfR above 1.41 mg/L had roughly 3 times the mortality risk of those below that threshold (HR 3.17). This was the strongest single predictor of death in the study, outperforming standard heart failure biomarkers.

What makes this finding especially relevant is that elevated sTfR predicted death even in heart failure patients who did not have anemia or systemic iron deficiency by standard measures. A study of 215 chronic heart failure patients with normal hemoglobin and normal systemic iron status found that those with sTfR above 1.65 mg/L had more than twice the risk of death (HR 2.14, 95% CI 1.22 to 3.75). This means tissue-level iron starvation, invisible to standard labs, is independently dangerous in heart failure.

Diabetes and Mortality

In 287 patients with type 2 diabetes and stable coronary artery disease followed for an average of nearly 4 years, sTfR showed an exponential relationship with death. Each 1-unit increase in the logarithm of sTfR was associated with a more than 4-fold increase in 5-year mortality risk (HR 4.24, 95% CI 1.43 to 12.58). This association remained significant after adjusting for hemoglobin, kidney function, inflammation markers, and neurohormonal activation.

All-Cause Mortality in the General Population

sTfR's predictive value extends beyond patients with known disease. In an analysis of 5,403 women who had not yet reached menopause from the U.S. general population (NHANES), followed for a median of 8.7 years, those in the highest third of sTfR levels had a 77% higher risk of death compared to those in the middle third (HR 1.77, 95% CI 1.05 to 2.98). The highest sTfR group was also at increased risk of developing chronic kidney disease. These associations held after adjusting for hemoglobin and ferritin.

Cancer Associations

A study that looked at a single point in time across 5,480 adults from NHANES found that those in the highest third of sTfR levels had a 53% higher rate of cancer compared to the lowest third (OR 1.53, 95% CI 1.15 to 2.02). The associations were strongest for sex-specific cancers, including prostate, testicular, breast, cervical, ovarian, and uterine cancers. Because this study captured a snapshot rather than tracking people over time, it cannot prove that elevated sTfR causes cancer, but it raises the possibility that tissue iron deficiency and increased red blood cell production may be linked to cancer biology.

Reference Ranges

sTfR reference ranges vary significantly depending on the assay your lab uses. There is no international standard, which means your result from one lab cannot be directly compared to a result from a different lab using a different method. This is the single biggest limitation of sTfR testing and the reason you should always compare your results within the same lab over time.

Two major assay families produce very different numerical ranges. One type of test (immunoturbidimetric, used in NHANES and many large reference labs) reports values around 3 to 5 mg/L for healthy adults. The other type (immunonephelometric) reports values around 1.0 to 1.6 mg/L. Both are measuring the same protein; they just use different measurement methods and reference materials.

These values are drawn from published research across multiple populations. Your lab will provide its own reference range for the assay it uses. The exact cutpoint matters less than the trend: if your sTfR is rising over serial measurements within the same lab, your tissue iron status is worsening.

Age, Sex, and Ethnicity Effects

sTfR levels are higher in children and decline through adolescence into adulthood. Boys tend to have slightly higher values than girls during childhood and adolescence, likely reflecting higher red blood cell production during growth. In one study of healthy adolescents, the mean was 1.39 mg/L in boys versus 1.23 mg/L in girls. Age, sex, and stage of puberty together predicted about 24% of the variation in sTfR levels.

Ethnicity also matters. Non-Hispanic Black children and women consistently show higher sTfR concentrations than non-Hispanic White and Mexican-American populations in NHANES data, even after accounting for iron status. No ethnicity-specific reference ranges have been formally established, but this difference means that a single universal cutpoint may not apply equally to all populations.

When Results Can Be Misleading

The within-person biological variation for sTfR is about 6% to 14%, depending on the study and sampling interval. This is much more stable than ferritin (about 27% variation) or serum iron (about 29%), but it still means a single measurement can be off by enough to cross a clinical threshold. A seasonal rhythm has also been documented, with peak-to-trough differences of about 12%.

Inflammation, despite the textbook claim that sTfR is "inflammation-proof," does influence results. A study of 1,001 rheumatology patients found that sTfR correlated positively with inflammatory markers like CRP, and patients with active inflammatory disease had significantly higher sTfR (mean 3.99 mg/L) than those with inactive disease (3.31 mg/L). The BRINDA project found that adjusting for inflammation reduced estimated iron deficiency prevalence by 4 to 15 percentage points, depending on the population.

Conditions that increase red blood cell production for reasons other than iron deficiency will also raise sTfR and can create false positives. These include hemolytic anemias (where red blood cells are destroyed faster than normal), certain blood cancers like chronic lymphocytic leukemia and high-grade non-Hodgkin's lymphoma, and use of erythropoietin-stimulating drugs. If your sTfR is elevated but you have one of these conditions, the elevation may reflect increased bone marrow activity rather than iron deficiency.

SGLT2 inhibitors, a class of diabetes and heart failure medications, can increase sTfR by about 20% over 12 weeks by stimulating red blood cell production. If you take empagliflozin or a similar drug, your sTfR may be higher than expected. Chronic proton pump inhibitor use (2 or more years) can cause genuine iron depletion by impairing iron absorption, leading to a true sTfR elevation that reflects real iron deficiency.

Tracking Your Trend

A single sTfR reading gives you useful information, but tracking your level over time is far more valuable. Because of assay variability, biological variation, and the influence of inflammation, one number can be misleading. Two or three readings from the same lab, spaced over months, reveal a trajectory that a single snapshot cannot.

If you are starting iron supplementation, sTfR is one of the earliest markers to respond. Studies show significant decreases within 3 weeks of oral iron supplementation, with continued improvement over 8 weeks. This makes it a useful tool for confirming that your iron therapy is actually working at the tissue level, not just raising your ferritin.

Get a baseline measurement. If you are actively treating iron deficiency, retest in 6 to 8 weeks to confirm a response. For ongoing monitoring of a chronic condition that affects iron metabolism, retest every 3 to 6 months. Always use the same lab and, if possible, the same assay to ensure your trend line is meaningful.